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Background: Advances in nanostructure materials are leading to novel strategies for drug delivery and targeting,
contrast media for magnetic resonance imaging (MRI), agents for hyperthermia and nanocarriers.
Superparamagnetic iron oxide nanoparticles (SPIONs) are useful for all of these applications, and in drug-release systems,
SPIONs allow for the localization, direction and concentration of drugs, providing a broad range of therapeutic
applications. In this work, we developed and characterized polymeric nanoparticles based on poly (3-hydroxybutyric
acid-co-hydroxyvaleric acid) (PHBV) functionalized with SPIONs and/or the antibiotic ceftiofur. These nanoparticles can
be used in multiple biomedical applications, and the hybrid SPION–ceftiofur nanoparticles (PHBV/SPION/CEF) can serve
as a multifunctional platform for the diagnosis and treatment of cancer and its associated bacterial infections.
Results: Morphological examination using transmission electron microscopy (TEM) showed nanoparticles with a
spherical shape and a core-shell structure. The particle size was evaluated using dynamic light scattering (DLS),
which revealed a diameter of 243.0 ± 17 nm. The efficiency of encapsulation (45.5 ± 0.6% w/v) of these polymeric
nanoparticles was high, and their components were evaluated using spectroscopy. UV–VIS, FTIR and DSC showed
that all of the nanoparticles contained the desired components, and these compounds interacted to form a
nanocomposite. Using the agar diffusion method and live/dead bacterial viability assays, we demonstrated that
these nanoparticles have antimicrobial properties against Escherichia coli, and they retain their magnetic properties as
measured using a vibrating sample magnetometer (VSM). Cytotoxicity was assessed in HepG2 cells using live/dead
viability assays and MTS, and these assays showed low cytotoxicity with IC50 > 10 mg/mL nanoparticles.
Conclusions: Our results indicate that hybrid and multifunctional PHBV/SPION/CEF nanoparticles are suitable as a
superparamagnetic drug delivery system that can guide, concentrate and site–specifically release drugs with
antibacterial activity.
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Superparamagnetic nanoparticles are used in multiple bio-
medical applications, such as for contrast medium in
magnetic resonance imaging (MRI)-based diagnosis, in
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unless otherwise stated.treatment [1]. Hyperthermia is a treatment were the
target tissue is exposed to temperatures slightly higher
than physiological to damage and kill cells.
There are many different superparamagnetic nanoparti-
cles; however, superparamagnetic iron oxide nanoparticles
(SPIONs) are currently the best option for biomedicine
because they are biocompatible with the body. Actually,
for diagnostics, gadolinium salts (Gd-DTPA) are the
gold standard contrast medium for MRI, but their reso-
lution and retention time in vivo remains low (2 mm
for MRI) [2-4]. However, Gd-DTPA have been linked tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Representative image of PHBV/SPION/CEF obtained by
transmission electron microscopy (TEM). Bar: 160 nm.
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levels. Therefore, it is important to find alternative con-
trast media that have low toxicity and better resolution for
MRI. In this field, SPIONs function as a more sensitive
contrast medium; the obtained images have better reso-
lution, and the particles have a better retention time
in vivo and are more biocompatible than Gd-DTPA [4].
The use of a SPION-like contrast medium for MRI is not
the only potential application of SPIONs. Theoretically,
SPIONs can be used for multiple actions, thus generating
multifunctional nanoparticles. SPIONs can be used for
hyperthermia applications and drug delivery [5], allowing
for the localized and controlled release of drugs.
The application of nanoparticles in vivo depends on
their physicochemical properties such as their hydropho-
bicity, net surface charge and size. These properties have a
direct impact on their biocompatibility, biostability and
toxicity. The use of SPIONs is limited because SPIONs
are not stable in physiological environments due to their
very reactive surface. SPIONs liberate Fe2+ ions, produce
oxidative stress via the release of reactive oxygen species
(ROS), and alter ion transport [6]. Lastly, SPIONs are not
stable in aqueous media because they tend to agglomerate
and precipitate [4]. To overcome these limitations, we
have proposed coating SPIONs with biocompatible mate-
rials to preserve all of their potential uses while preventing
their toxicity [7].
The development of nanotechnologies that utilize bio-
compatible and biodegradable polymers has provided new
tools for diagnostic and therapeutic strategies in biomedi-
cine [8], wherein one of the most important areas is drug
delivery. Current novel therapeutic strategies include the
delivery of cell tissue-specific drugs, the use of agents that
allow for the imaging of release sites [9], delivery systems
that can cross epithelial and endothelial barriers [10], the
intracellular delivery of macromolecules, improvements in
drugs with poor water solubility, the co-release of thera-
peutic agents, and an improvement in effective therapies
[11,12]. For these applications, a biocompatible and bio-
degradable polymer is the best candidate for a SPION
coating because this type of coating may decrease their
natural reactivity and maintain their physical properties.
Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), a
polymer that has recently been used for drug delivery and
tissue engineering [13], is cost effective and has physico-
chemical properties similar to those of the most widely
used polymers such as poly(L-lactide) [14], poly(D,L-lac-
tide-co-glycolide) [15-18], poly-sebacic anhydride [19] and
poly-ε-caprolactone [20-22].
One aim in drug delivery is to transport antibiotics. In
this area, we determined that PHBV can be used to encap-
sulate and deliver the antibiotic ceftiofur in microparticles
[23,24] and PHBV can interact with β-lactams to form
a new microcomposite with specific physicochemicalproperties. We analyzed the same antibiotic that was pre-
viously assayed (ceftiofur), and we incorporated SPIONs
into PHBV nanoparticles to generate a new nanocom-
posite. Furthermore, we analyzed the molecular struc-
ture and the cytotoxicity of PHBV nanoparticles loaded
with SPIONs and ceftiofur (PHBV/CEF/SPION); for
controls, we used each component and nanoparticles
with different combinations of their components: PHBV
nanoparticles with only ceftiofur (PHBV/CEF) and PHBV
nanoparticles with only SPIONs (PHBV/SPION).
Due to the potential uses of SPIONs and the advantages
of polymeric nanoparticles, PHBV/CEF/SPION nanoparti-
cles could (i) be used as a nanocarrier for tissue-specific
drug delivery, (ii) allow for MRI-based diagnostics and for
therapy using their antibacterial activity or hyperthermia
using only one injection, and (iii) be used as a multifunc-
tional treatment for hyperthermia and for the release of
antibiotics at an infection site.
Results and discussion
TEM images (Figure 1) show PHBV/CEF/SPION nano-
particles with a core-shell structure, a spherical shape, a
smooth surface and a moderately uniform size distribu-
tion. This image shows nanoparticles with dense black
spots inside. The mean size (diameter, nm) of the for-
mulated PHBV/CEF/SPION measured using DLS was
243.0 ± 17.
To determine the amount of ceftiofur that was able to
incorporate into the PHBV nanoparticles, we analyzed the
individual components of these lyophilized nanoparticles
using UV-visible (UV–VIS) spectroscopy (Figure 2). The
UV–VIS spectra of nanoparticles with different combina-
tions of components are shown: PHBV nanoparticles with
ceftiofur, PHBV nanoparticles with SPION and PHBV
nanoparticles with SPION and ceftiofur. For controls, we
used empty PHBV nanoparticles and free ceftiofur.





















Figure 2 UV–VIS spectroscopy of PHBV nanoparticles and
ceftiofur.
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shows an intense broad band centered at approximately
320 nm. The deconvolution of the signal at 320 nm
showed that it mainly corresponds to the superposition of
four peaks, namely, two low-intensity absorption peaks
centered at 235 and 294 nm and two more intense absorp-
tion peaks centered at 265 and 325 nm. The lower energy
and higher intensity of the latter absorbances correspond
to π-π* transitions for a highly delocalized system. Because
of the molecular structure of ceftiofur, this absorption
band could be assigned to the polyenone arising from the
alkyloximino C =N- chromophore modified by the thiazo-
lyl moiety. The peak observed at 294 nm with lower inten-
sity could correspond to the C =O chromophore from the
amide group, which is also near the thiazolyl group. The
high intensity band at 265 nm could also be assigned to
π-π* transitions centered in the furan-carboxylic-thioester,
whereas the lower intensity peak at higher energy (or
lower wavelength) most likely arises from the C = O
lactam moiety. Absorption by the carboxylic acid-
dihydrothiazine chromophore is expected to occur at
higher energies, and thus it was not observed in the
spectrum.
PHBV nanoparticles could potentially act as a nanocar-
rier that incorporates ceftiofur; thus, we evaluated the
encapsulation efficiency (EE%) of ceftiofur. The EE% of
lyophilized nanoparticles, measured using Ultra perform-
ance liquid chromatography (UPLC) and UV–VIS absorb-
ance at 302 nm, was compared with a previously set
calibration curve. The PHBV/CEF nanoparticles contain
11.41 wt% ceftiofur, and the PHBV/CEF/SPION nano-
particles contain 11.43 wt% ceftiofur. As the SPIONs
produce high levels of noise in the UV–VIS spectrum,
we corroborated this result using UPLC with threeindependent samples. The %EE of ceftiofur in PHBV
nanoparticles was 45.5 ± 0.6.
To assess the composition and molecular architecture
of the new PHBV/CEF/SPION nanoparticles and their
precursors, FT-IR spectra were analyzed (Figure 3A-D).
It is well-known that the ceftiofur molecule contains dif-
ferent functional groups that can be identified in an in-
frared spectrum; therefore, the most representative
signals of the drug could be assigned.
From the IR spectrum, it is possible to assign signals
corresponding to the carbonyl, thioester, amide and
amine groups of ceftiofur at the bond-stretching fre-
quencies of 1771, 1709, 1661 and 1661 cm−1, respect-
ively. The presence of these signals helps to corroborate
the formation of the drug-polymer nanoconjugate.
The spectra of the precursors of crystalline PHBV and
SPION correspond to those expected for both (Additional
file 1). However, some significant changes are observed in
the spectrum of PHBV when the polymer is prepared in
the form of nanoparticles. The most prominent bands in
the spectrum of the polymer, one band centered at ap-
proximately 1530 cm−1 in the resonance region of N-H
and O-H oscillators and another band at 1637 cm−1 that
is assignable to the carbonyl ester stretching strongly asso-
ciated with hydrogen bonding, are severely decreased.
However, the normal absorption expected for the ester
carbonyl group at 1737 cm−1 became clearly detectable in
the NPs. Both features clearly indicate that the confine-
ment of the polymer in such a small volume appears to
produce a drastic loss of water.
The PHBV/CEF composite has a strong band centered
at 1732 cm-1, possibly due to the superposition of the
absorption of the ester with the carboxylic acid group of
ceftiofur. Moreover, the band corresponding to N-H ab-
sorption in ceftiofur (Additional file 1) is broadened and
shifted to a lower energy in the presence of the polymer;
thus, this band shows a relative intensity as large as or
even larger than that of the PHBV crystals. Meanwhile,
the width of the band region corresponding to C = O
stretching vibrations remains practically unaltered. Fur-
thermore, the addition of SPIONs induces a decrease in
the intensity of the spectrum and a well-known red shift
of the bands of the C =O oscillators, whereas the band
of the N-H absorption remains practically unaltered. In
the PHBV/SPION/CEF nanocomposite (Figure 3C), the
spectrum in these regions is better resolved in general,
although the intensity is lower. Nevertheless, there is still
much overlapping of vibrational bands. However, the
particular frequency values of the absorption band com-
ponents may at least be partially attained by analyzing
the second derivative of the spectrum. Thus, an analysis
of the spectral changes of ceftiofur that are associated
with the formation of the nanocomposite is discussed
below.


























































































Figure 3 FTIR spectroscopy of PHBV nanoparticles. A) empty PHBV nanoparticles, B) PHBV/SPION nanoparticles, C) PHBV/SPION/CEF nanoparticles
and D) PHBV/CEF nanoparticles. The controls, FTIR of ceftiofur, SPION and PHBV crystal are in Additional file 1.
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the polymer and the metal oxide, this analysis of vibra-
tions has been limited to the functional groups that are
potentially more reactive: electrophilic or nucleophilic
centers that can interact with the polymer and the metal
oxide. From such a perspective, the behavior of electron
donor centers (principally the carbonyl groups), as well
as that of acceptor centers (e.g., the hydrogen atoms in
the N-H and -O-H groups), is particularly interesting. In
the polymer, the donor functionality of the carbonyl
groups in the polyester is certainly the most important.
However, the activity of the -COOH groups at the end
of the polymer chains should also be considered. The
SPION surface itself is rich in acceptor centers, coordi-
nately unsaturated iron atoms and O-H groups, which
are normally found in stabilized oxide surfaces.
In the PHBV/CEF (Figure 3D) and PHBV/SPION/CEF
composites (Figure 3C), the amine and amide N-H pro-
tons of ceftiofur strongly interact with the polymer. Thus,
the bands centered at 3522 and 3393 cm−1 in ceftiofur,
which we have assigned to asymmetric and symmetric N-
H stretching, are shifted to lower energy in the composite:
3421 and 3250 cm−1, respectively. The stretching vibration
of the secondary amide N-H is found at a relatively low
wavenumber, 3289 cm−1, in ceftiofur, indicating an associ-
ation in the pristine compound; thus, the red shift ob-
served in the composites is rather moderate. The addition
of polymer affects the acidic centers of ceftiofur in amanner that does not change after the addition of
SPIONs. As mentioned above, the polymer also contains
some acidic centers; thus, it is expected that the addition
of PHBV should also affect the carbonyl oscillators in cef-
tiofur. Such an effect is clearly observed in the stretching
vibration of the C =O amide bond. Indeed, a red shift of
approximately 14 cm−1 is detected in both composites.
To clarify the molecular structure of the PHBV nano-
particles, we analyzed these nanoparticles using DSC
(Figure 4). The thermograms show a change in the crys-
talline behavior of the nanostructured PHBV. This fact
should be attributed to the loss of degrees of freedom of
the polymer due to its nanostructure; this loss could be
favored by an increase in the amorphous fraction in the
PHBV nanoparticles. Additionally, the PHBV-CEF nano-
conjugate thermogram shows behavior that differs from
that of the PHBV NP precursor because ceftiofur is in-
corporated inside of the cavities generated by the poly-
meric chains, preventing further ordering of the chains.
Thus, the disorder in the polymeric chains and the
amorphous fraction increases relative to the empty
PHBV nanoparticles. Assays of PHBV/CEF showed that
it is more amorphous than PHBV NP because ceftiofur
inserted between the polymeric chains via hydrogen
bridges and because ceftiofur broke some of the polymeric
chains that form aldehyde groups in the valerate group of
PHBV. The conformation of PHBV/SPION is similar to
that of PHBV/CEF. However, PHBV/CEF/SPION has a
Figure 4 DSC assay for PHBV nanoparticles. The melting temperature for each sample is shown at the bottom.
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crystalline fraction of PHBV/CEF/SPION is dramatically
diminished; it is possible that ceftiofur and SPION inter-
leave between polymeric chains, preventing any inter-
action, and this fact may explain the huge difference atFigure 5 Possible interactions between ceftiofur and the polymer in t
UV–VIS and DSC assays.3500 cm−1 between Figure 3B/D and 3C. All of these re-
sults suggest a possible molecular structure for the PHBV/
SPION/CEF nanoparticles. The interactions between
ceftiofur and the polymer are shown in Figure 5. We
have demonstrated that SPIONs and ceftiofur arehe nanoparticles according to data obtained through FTIR,
Figure 7 Determination of the antimicrobial activity of PHBV
nanoparticles, ceftiofur and SPIONs against Escherichia coli
(ATCC 25922) measured using the agar diffusion method at
24 hours of incubation.
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act with the polymeric chains; thus, we need to further
demonstrate that the SPIONs and ceftiofur do not lose
their physicochemical and biological properties. Magnetic
characterization using VSM measurements demonstrated
the superparamagnetic behavior of the PHBV/SPION and
PHBV/CEF/SPION nanoparticles (Figure 6). This fact
proves that PHBV/SPION and PHBV/CEF/SPION nano-
particles have biomedical applications in MRI, hyperther-
mia and drug delivery to specific tissues.
The antimicrobial activity of PHBV/CEF/SPION nano-
particles against Escherichia coli was measured using the
agar diffusion method. These nanoparticles showed posi-
tive antibacterial activity. The inhibition halo of PHBV/
CEF/SPION nanoparticles was 29 mm and that of free
ceftiofur was 36 mm. PHBV nano particles without CEF
did not show an inhibition halo (Figure 7). Live/dead
bacterial viability assays further showed that the viability
of bacteria decreased in a dose-dependent manner in
samples treated with PHBV/CEF/SPION (Figure 8A-E).
The positive control (30 μg/mL ceftiofur, Figure 8F)
showed results similar to those of 20 μg/mL PHBV/
CEF/SPION (Figure 8E).
We lastly assayed the toxicological effects of 0.1 μg/
mL to 10,000 μg/mL of polymeric nanoparticles in a
HepG2 cell line using fluorescence microscopy (Figures 9
and 10). We used the HepG2 cell line because PHBV/
CEF/SPION have potential applications in biomedicine
by intravenous administration. Thus it is very important
determine the toxicology in hepatic cells. Figure 9 shows
a statistical analysis of the number of live and dead cells
per field from a double-blind analysis of 1200 images.
We show an example of these images in Figure 10 (live
cells in green and dead cells in red). The background
fluorescence intensity for the 1,000 μg/mL and 10,000 μg/
mL samples was high because at high concentrations, theFigure 6 Hysteresis loop of PHBV/SPION/CEF nanoparticles
measured using a vibrating sample magnetometer (VSM).
All samples showed superparamagnetic characteristics.nanoparticles tended to deposit on the sample, hindering
the washing. For these samples, we used fluorescence in-
tensity plots to quantify the number of live and dead cells
per field (bottom, Figure 10). Treatment with PHBV,
PHBV/CEF, PHBV/SPION or PHBV/CEF/SPION nano-
particles at 0.1 μl/mL to 10,000 μg/mL did not cause
significant cell death in the HepG2 cells (ANOVA p-
value >0.05) (Figure 9). A more detailed analysis shows
that the PHBV NP, PHBV/SPION and PHBV/CEF/SPION
nanoparticles have IC50 > 10,000 μg/mL and that the
PHBV/CEF nanoparticles have IC50 = 10,000 μg/ml. Statis-
tical analysis shows that only PHBV/CEF caused signifi-
cant differences in cell viability, but at doses much higher
than physiological doses (10,000 μg/ml) (ANOVA and T-
test < 0,05). The toxicity of PHBV/CEF is primarily caused
by the high concentration of ceftiofur in the external shell
of the nanoparticles.
Cell viability was measured using an MTS assay
(Figure 11). The MTS assay showed that the IC50 of the
empty PHBV, PHBV/SPION and PHBV/CEF/SPION
nanoparticles was higher than 10,000 μg/mL and that the
IC50 of PHBV/CEF nanoparticles was 10,000 μg/mL. Al-
though the viability of the HepG2 cells decreased after
treatment with PHBV/CEF nanoparticles at 10,000 μg/ml,
the number of dead cells did not increase. This finding is
very important because it indicates that the % viability de-
creased but not enough to kill the cells.
In this work, we report on the use of SPIONs in a formu-
lation of PHBV nanoparticles loaded with ceftiofur and on
the use of SPIONs as a carrier with a superparamagnetic
Figure 8 Determination of the antibacterial activity of PHBV/SPION/CEF against Escherichia coli (ATCC 25922) at 24 hours of incubation
using LIVE/DEAD viability assays. A) control (without treatment), B-E) treatment with 0.1, 1, 10 and 20 μg/ml of PHBV/SPION/CEF nanoparticles,
F) treatment with free ceftiofur 30 μg.
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a spherical shape with a core-shell structure and a smooth
surface. A TEM image (Figure 1) shows nanoparticles with
dense black spots inside; these spots show that the SPIONs
were well incorporated into the PHBV nanoparticles. The
PHBV/SPION/CEF size (243.0 ± 17 nm) is optimal to have
low cytotoxicity and high retention in vivo [6]. The results
also show that interactions between PHBV, SPIONs and
ceftiofur can change the conformation of the polymeric
chains and their properties to favor the entrapment of the
drug molecule. In addition, the structure of the polymer
and its functionality suggest that the release process of theHepG2

























Figure 9 Cytotoxicity of PHBV nanoparticles at 0.1, 1, 10, 100,
1,000 and 10,000 μg/mL against HepG2 cells using the LIVE/DEAD
viability/cytotoxicity assay.drug should be controlled by hydrolysis of the polymeric
chains. The changes in the spectrum of ceftiofur men-
tioned above can be explained by considering a model in
which the PHBV/CEF nanocomposite contains a SPION
core. Ceftiofur is anchored to this core by a Lewis donor
acceptor interaction through the amide and carboxylic C =
O moieties, whereas its amine groups simultaneously inter-
act with the polymer, forming the external shell of the
nanoparticles.
Given the nature of the interactions in this nanocom-
posite, the system should be sensitive to changes in the
pH of medium, a feature that is interesting from the per-
spective of the encapsulation and release of the drug.
FT-IR analysis of the products described in this work
(Figure 3A-D) demonstrated the efficiency of the method
used to prepare the PHBV nanoparticles and also contrib-
uted to a better understanding of the phenomena involved
in this process. Indeed, the results described above show
that an essential variable in this procedure is the creation
of conditions that produce polymer self-aggregation. The
dependence on these conditions, along with other factors,
forces the polymers to a lower energy by saturating, at
least partially, the ester donor moieties; this saturation oc-
curs because the ends of the chains displace water mole-
cules from these sites, and thus, the volume can decrease
to the desired nanometer scale. Such a condition appears
to fail in the presence of ceftiofur, where hydration also
appears to be necessary to stabilize the excess of donor
Figure 10 Representative images of the cytotoxicity of PHBV/SPION/CEF against HepG2 cells using the LIVE/DEAD viability/cytotoxicity
assay. The concentration of nanoparticles is in the right corner. Bottom: fluorescence intensity plots of higher concentrations. Bar: 40 microns.
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PHBV/CEF nanoparticles (Figure 3D) is different and a bit
more complex than that previously described for isolated
ceftiofur (Additional file 1). The deconvolution of this
spectrum showed a sharp band at 227 nm, which is char-
acteristic of PHBV nanoparticles (Figure 3A), and an
absorbance at approximately 337 nm that apparently
corresponds to a wavelength shift in the drug-polymer
ceftiofur interactions. The band assigned to the imide
chromophore undergoes a relatively strong blue shift,
most likely due to an inductive effect between the NH2












Figure 11 Cytotoxicity of PHBV nanoparticles at 0.1, 1, 10, 100, 1.000polymer. These observations are in good agreement
with the infrared spectra described below. Indeed, the
observed shifts of the electronic absorption bands indi-
cate that the polymer provides the drug with a micro-
environment that differs from the pristine bulk state. In
this case, these shifts are caused not only by dielectric
effects but also by rather specific interactions between
the donor and acceptor chromophore centers of ceftio-
fur and the respective groups. Along with hydration
water, the electrophilic and nucleophilic groups of cef-
tiofur, which are available within the polymer backbone,






and 10.000 μg/mL against HepG2 cells using the MTS assay.
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only the carboxylic groups at the polymer-chain ends), it is
expected that the principal contribution to the modifica-
tion of the electronic configuration of ceftiofur should be
the formation of hydrogen bonds between the ester car-
boxylic residues within the polymer backbone and the pro-
tons from the thiazolyl-amine groups. Such interactions
seem to mainly be caused by the hypsochromic effects
produced in both the imide and amide chromophores.
The presence of SPIONs in the nanocomposite provides
a high concentration of new strong electrophilic sites.
These sites are able to compete favorably to stabilize the
excess of charge on the C =O groups of ceftiofur and
polymer. Indeed, these groups often appear to prefer to
interact with SPIONs, thus replacing polymer chain termi-
nals as well as exogenous water molecules from the elec-
trophilic sites in ceftiofur and the polyester. In the case of
π-π* transitions in the polyenone chromophores, these
types of interactions are expected to induce bathochromic
effects. Of the two bands in the PHBV/CEF nanocompos-
ite assigned above to the polymer, only the low energy
broad band is detected at approximately 370 nm in the
spectrum of PHBV/SPION/CEF. This red shift is also the
most likely reason that the characteristic band of the poly-
mer nanoparticles at 227 nm is not detected in the nano-
composite with SPIONs. In the case of ceftiofur confined
in the nanoparticle, the amide-CO-based chromophore is
supposed to be more active in the interaction with
SPIONs than the chromophores based on the imide-C =
N. Thus, the fact that the addition of SPIONs to the nano-
particles only moderately affects the position of the lower
energy band of ceftiofur in the electronic spectrum of the
PHBV/CEF nanocomposite corroborates the assignment
of this absorption to the imide unit proposed above. In
contrast, in the case of the amide band, the presence of
SPIONs not only reverses the blue shift caused by the
hydrogen bonding of the thiazolyl moiety of ceftiofur with
the polymer but also further induces a red shift of ap-
proximately 15 nm with respect to the position of this
band in the pristine drug. A similar (but more moderate)
effect of approximately 7 nm is observed in the band
assigned to the ceftiofur thiolester carbonyl, whereas the
band proposed for the lactam carbonyl remains practically
unaltered.
Lastly, the PHBV nanoparticles showed low cytotoxicity
at high concentrations in HepG2 cells. These results in-
dicate that PHBV is a suitable agent for entrapment
antibiotics and further demonstrate its biocompatible
properties.Conclusions
Our results indicate that these nanoparticles have poten-
tial for use in hyperthermia and could be used for drugdelivery. PHBV/CEF/SPION have potential applications
as a multifunctional platform because they could be used
for MRI, hyperthermia applications and the release of
antibiotics at an infection site with only one injection.
The encapsulation of ceftiofur in PHBV nanoparticles is
only one example of cephalosporin encapsulation. In
theory, any cephalosporin with the same physicochemi-
cal properties as ceftiofur will behave similarly.
The size and shape of the PHBV/CEF/SPION nanopar-
ticles can be seen in the TEM image (Figure 1). UV–VIS
spectroscopy of these nanoparticles (Figure 2) shows the
presence of all the desired components, and the efficiency
of encapsulation was calculated using a calibration curve.
Using FT-IR spectroscopy (Figure 3), we analyzed the in-
teractions between ceftiofur, SPION and the polymer.
These data were correlated with the DSC results (Figure 4)
and were also used to do the model in Figure 5. The
SPION activity of the PHBV nanoparticles was measured
by VSM (Figure 6), and the antimicrobial activity of ceftio-
fur was measured by Kirby-Bauer assay (Figure 7) and mi-
croscopy (Figure 8). The toxicity of these nanoparticles
was measured by microscopy in HepG2 cells. The per-
centage of live cells was plotted in Figure 9, and in
Figure 10 an example of the microscopy photos is
shown. Finally we measured the percentage of viability
of the HepG2 cells by MTS (Figure 11).
The characteristics of PHBV/CEF/SPION nanoparticles
give them many possible applications in biomedicine.
Their superparamagnetic and antibacterial properties are
very useful for treating infections in low irrigation sites,
for example bone infections, because these nanoparticles
allow the antibacterial dose to be localized to the site of
infection. This ability can be used to reduce the doses of
antibiotics, which at the same time would decrease associ-
ated adverse drug reactions. On the other hand, PHBV/
CEF/SPION nanoparticles can be used in hyperthermia at
infection sites, and this capability can be used to treat pa-
tients with bacterial infections associated with cancer.
Vulvar, prostate, lung, gallbladder, colon, and stomach
cancer have all been associated with different bacterial
infections in these organs. Eliminating the infection in
the cancer site can be critical to achieving tumor resec-
tion and decreasing cancer recurrence. For this reason,
therapy with PHBV/CEF/SPION can be very useful for
killing cancer cells and eliminating infection in the tar-
get tissue, all at the same time and with very low doses
of antibiotics.Methods
Preparation of PHBV nanoparticles
PHBV/CEF/SPION nanoparticles were synthesized using
the water–oil-water (w1/o1/w2) double emulsion with
solvent-evaporation method. This protocol was described
Solar et al. Journal of Nanobiotechnology  (2015) 13:14 Page 10 of 12previously [7,23], but in this case it was slightly modified.
For the experiments, 100 μL of ceftiofur (kindly provided
by Centrovet (Santiago, Chile) dissolved in methanol
(100 mg/mL) (Merck, Germany) was mixed with 300 μL
of a SPION suspension (magnetite, BioPAL Inc, MS, USA)
(1.65 mg/mL) and was added to 1 mL of PHBV (6.25 mg/
mL) (Sigma-Aldrich, St. Louis, MO, USA) dissolved in
dichloromethane (DCM) (Merck, Germany). A first w1/o1
emulsion was prepared by sonication for 40 s at 100%
amplitude (VCX130 ultrasonic processor, Sonics &
Materials, CT, USA) over an ice bath. The water-in-oil
emulsion was further emulsified under the same condi-
tions in 2 mL of an aqueous solution of polyvinyl alcohol
(PVA) (5 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA).
The w1/o1/w2 emulsion was immediately poured into a
beaker that contained 30 mL of PVA solution (0.5 mg/
mL) and was stirred in a hood under an exhaust fan for
16 h, allowing the solvent to evaporate. The solidified
nanoparticles were harvested by centrifugation and
washed with distilled water three times using an Amicon
Ultra-4 centrifugal filter (Millipore, Billerica, MA, USA)
with a molecular weight cut-off of 10 kDa. The PHBV/
CEF/SPION were either stored at 4°C for immediate use
or freeze-dried in liquid nitrogen and lyophilized for stor-
age at −80°C for later use. We carefully synthesized empty
PHBV nanoparticles (PHBV NP) using the same protocol
without SPIONs or ceftiofur. PHBV/SPION nanoparticles
were prepared using the same protocol but without ceftio-
fur, and PHBV/CEF nanoparticles were prepared using the
same protocol but without SPIONs.Transmission electron microscopy (TEM)
The morphological examinations of the nanoparticles
were performed as we described previously [23,24], using
a transmission electron microscope (Phillips-TECNAI 12
BIOTWIN EM Microscope, FEI Company, Hillsboro, OR)
at an acceleration voltage of 80 kV. The TEM sample was
prepared by depositing 0.5 mL of the nanoparticle suspen-
sion (1.0 mg/mL) onto a 300-mesh carbon-coated copper
grid (Electron Microscopy Sciences, PA, USA) that had
been previously hydrophilized under UV light (Electron
Microscopy Sciences, Hatfield, PA). The samples were
blotted away after 20 min of incubation, and the grids
were negatively stained for 5 min at room temperature
with freshly prepared and sterile-filtered 2% (w/v) uranyl
acetate aqueous solution (Electron Microscopy Sciences,
PA, USA). Then, the grids were washed twice with dis-
tilled water and air-dried prior to imaging.Dynamic light scattering (DLS)
The diameter (nm) and ζ potential (mV) of the nanoparti-
cles were analyzed by dynamic light scattering (DLS) in
the Zetasizer Nano ZSP 3000 (Malvern Instruments, UK)as we described previously [12,23,24]. Each preparation
was dissolved in 1 mL phosphate buffered saline (Merck,
Germany) at pH 7.4, and the measurements were carried
out on 3 independent formulations (batches).
UV–VIS spectroscopy
UV–VIS spectroscopy was used to measure the lyophi-
lized nanoparticles. The nanoparticles were analyzed using
a Shimadzu spectrophotometer (UV-2450, Columbia,
USA). We analyzed PHBV crystals (PHBV), empty PHBV
nanoparticles (PHBV NP), PHBV/SPION nanoparticles,
PHBV/CEF nanoparticles and PHBV/CEF/SPION nano-
particles. The data were analyzed using Origin software
(6.0, Northampton, USA).
FTIR spectroscopy
We lyophilized PHBV, PHBV NP, PHBV/SPION and
PHBV/CEF/SPION nanoparticles. Each lyophilized nano-
particle was mixed with KBr (Sigma-Aldrich, St. Louis,
MO, USA). These samples were used to make pills that
were 1 cm in diameter. Each pill was analyzed using
Bruker equipment (Vector 22, Hardtstrabe, Karlsruhe,
Germany), and our data were collected using OPUS
software (Optical user software, Hardtstrabe, Karlsruhe,
Germany). Thereafter, the data were analyzed using
Origin software (6.0, Massachusetts, USA).
Differential scanning calorimetry
We lyophilized PHBV, PHBV NP, PHBV/SPION and
PHBV/CEF/SPION nanoparticles. Each nanoparticle sam-
ple was weighed and then analyzed using a Mettler Toledo
instrument (DSC822-E module, Barcelona, Spain) from
25°C to 250°C. The data were analyzed using Origin soft-
ware (6.0, Massachusetts, USA).
Ceftiofur entrapment efficiency
The ceftiofur entrapment efficiency was analyzed using
UV–VIS spectroscopy. We obtained a calibration curve
for ceftiofur and measured different concentrations of
ceftiofur at 302 nm using a Shimadzu spectrophotom-
eter (UV-2450, Columbia, USA). We then measured the
lyophilized PHBV/CEF/SPION nanoparticles at 302 nm
using the same equipment and calculated the amount of
ceftiofur in the nanoparticles.
Alternatively, the ceftiofur entrapment efficiency was
analyzed by an extraction method described previously
[25]. Experimentally, 10 mg of PHBV/CEF/SPION was
dissolved in 1 mL of DCM followed by the addition of
5 mL PBS buffer (pH 7.4), and it was then agitated in an
orbital shaker maintained at 37°C for 24 h at 100 rpm.
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performance liquid chromatography (UPLC). Each sample
was measured in triplicate, and the actual drug loading
and drug encapsulation efficiency (EE) were calculated
using the following equations:
Theoretical drug loading ¼ drug total= drug totalþpolymerð Þ
Actual drug loading ¼ drug encapsulated= drug totalþpolymerð Þ
Encapsulation efficiency¼ðactual drug loading=theoretical drug
loadingÞ100%
Cell cultures
HepG2 cells (ATCC NUMBER HB-8065) were obtained
from ATCC at ampule passage N° 74. These cells were
cultured in MEM (Gibco, Invitrogen, Life Technologies,
Grand Island, NY, USA) supplemented with 10 v/v% FBS
Hyclone (Thermo Scientific, Utah, USA), 100 U/mL peni-
cillin Hyclone (Thermo Scientific, Utah, USA), and
100 μg/mL streptomycin Hyclone (Thermo Scientific,
Utah, USA) at 37°C under a humidified atmosphere of 5%
CO2 to passage N° 76. These cells were used in all
experiments.
Antibacterial activity
Antimicrobial susceptibility was measured using the
agar diffusion method as we performed previously [23]
and with live/dead bacterial viability assays (Invitrogen
Corporation, Carlsbad, USA). The tests were performed
in triplicate against Escherichia coli (ATCC 25922), and
we analyzed the antibacterial activity of PHBV/CEF/
SPION. The agar diffusion method was conducted in
accordance with the National Committee for Clinical
Laboratory Standards (NCCLS) [26]. The inoculum was
prepared from a Mueller-Hinton plate that had been
streaked with a single colony from an initial subculture
plate and incubated for 18 to 24 h. The test involved in-
oculating Mueller-Hinton medium and adjusting the
inoculum to 1.5 × 108 CFU/mL (equal to a 0.5 McFar-
land turbidity standard). SPIONs and PHBV/SPIONs
(20 μg) were used as negative controls, and ceftiofur
(30 μg) was used as a positive control. The diameter of
each zone of inhibition was determined to the nearest
millimeter after 24 h of incubation. In the live/dead
bacterial viability assays, 1 mL of 1.5 × 108 CFU/mL
Escherichia coli and PHBV/CEF/SPION (0.1, 1, 10 and
20 μg/mL) were added to tubes with 3 mL of Mueller-
Hinton liquid medium. As a negative control, we used
0.9% NaCl (Sigma-Aldrich, St. Louis, MO, USA), and as a
positive control, we used ceftiofur (30 μg/mL). The live/
dead bacterial viability assays were conducted according
to the manufacturer’s protocol. After 24 h of incubation,
each sample was mounted on a cover slip and visualized
using laser scanning confocal microscopy (Axiovert
100 M Microscope, Carl Zeiss, Germany).Vibrating sample magnetometer (VSM)
The magnetic properties of the magnetite, PHBV/SPION
and PHBV/CEF/SPION nanoparticles were performed as
we described previously [7] using a vibrating sample
magnetometer (VSM). The hysteresis loop was measured
at 300 K as a function of an external applied field.
Cytotoxicity assays for polymeric nanoparticles
Cell viability was examined using the MTS CellTiter 96
AQ Non-Radioactive Cell Proliferation assay (Promega,
Madison, USA) as we described previously [23]. Alterna-
tively, we used the LIVE/DEAD Viability/Cytotoxicity kit
for mammalian cells (Invitrogen Corporation, Carlsbad,
USA) following the manufacturer’s protocols. Cells were
treated for 24 h with the following: PHBV NP, PHBV/
SPION or PHBV/CEF/SPION at 0.1, 1, 10, 100, 1,000
and 10,000 μg/mL. As a negative control, the cells were
treated with just vehicle (MEM medium without serum).
In the LIVE/DEAD Viability/Cytotoxicity assay, the
cells were cultured in CultureSlides from BD Falcon (8
wells) with MEM supplemented 10 v/v% FBS at 37°C
under a humidified atmosphere of 5% CO2. The seeding
was 60000 cells per well, and the cells were used after
24 hours and 90% confluence. Each sample was tested in
triplicate with three independent experiments, and 10
images were examined at 40× (Olympus U-RLF-T mi-
croscopy) to count the live and dead cells for each treat-
ment. As a cytotoxicity control (100% cell death), the
cells were treated for 30 minutes with 70% methanol
(Merck, Germany). The statistical analyses (two-way
ANOVA and T-test) were conducted using GraphPad
Prism 5.0 software (California, USA).
In the MTS cell proliferation assay, the seeding was
75000 cells per well in a 96-well plate. Each sample was
measured in triplicate using three independent experi-
ments. Before the addition of MTS, the cells were
washed with Hank’s medium. The cells were incubated
with MTS for 1 h at 37°C under a humidified atmos-
phere of 5% CO2. The supernatant was collected in an
Eppendorf tube and was centrifuged at 13000 rpm for
15 min. The measurement was performed using 90 μL
of supernatant per well in a 96-well plate in an ELISA
reader at 450 nm (Thermo Scientific, USA). SPIONs can
interfere with the spectrometry readings. To correct
these data we used the same concentration of nanoparti-
cles in a 96-well-plate without cells. As controls we used
untreated cells for 100% viability and only medium for
0% viability. The statistical analyses (two-way ANOVA
and t-test) were performed using GraphPad Prism 5.0
software (California USA).
Statistical analysis
We evaluated the significance of differences in viable
and dead cells between the treatments with PHBV NP,
Solar et al. Journal of Nanobiotechnology  (2015) 13:14 Page 12 of 12PHBV/SPION, PHBV/CEF/SPION and without nano-
particles. We used two-way ANOVA to evaluate the dif-
ferences between the treatments and the t-test to assess
the differences between the treatments and the negative
control. We calculated all of the statistics using Graph-
Pad Prism 5.0 software (California, USA).
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FT-IR spectra of ceftiofur, SPION and PHBV crystal. These data were used
as controls to analyze the spectra in Figure 3.
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